Surveillance Recommendations for CDKN2A Mutation Carriers

Eligibility Criteria

CDKN2A p16 mutation carriers qualify for surveillance with at least one affected first-degree relative, reaching 99% consensus and Grade 1 recommendation 1
CDKN2A p16 mutation carriers also qualify for surveillance regardless of family history, with 77% consensus and Grade 1 recommendation 1

Begin surveillance at age 40 years, or 10 years younger than the youngest affected relative with pancreatic cancer, as recommended by the European Society of Gastrointestinal Endoscopy 1, 2, 3
For germline mutation carriers, including CDKN2A, surveillance should begin 5 years earlier than for individuals with familial pancreatic cancer only 2, 3

Use EUS and/or MRI/MRCP for both baseline and follow-up surveillance, with 92.1% consensus for baseline and 89.5% for follow-up (Grade 2) 1, 2, 3
The European Society of Gastrointestinal Endoscopy recommends alternating between MRI/MRCP and EUS at 12-month intervals 5

CA19-9 should be used as an additional surveillance test when worrisome features are detected on imaging, with 76.5% consensus and Grade 2 recommendation 2, 3
Routine testing with fasting blood glucose and/or hemoglobin A1c should be performed, with 76.1% consensus and Grade 2 recommendation 2, 3

Annual surveillance (12-month intervals) is recommended when no pancreatic abnormalities are present, with 90.4% consensus 2, 3, 6
For low-risk findings, continue 12-month surveillance intervals, with 88.6% consensus and Grade 2 recommendation 2, 3
For concerning abnormalities, repeat imaging within 3-6 months 2, 3

Worrisome features requiring EUS-FNA include mural nodule, solid component, and main pancreatic duct dilation 1, 2, 3
Surgical resection is indicated for mural nodule, enhanced solid component, symptoms, and main pancreatic duct ≥10 mm 1, 2, 3

Do not delay surveillance until age 50 in CDKN2A carriers, as they require earlier screening starting at age 40 due to younger age of onset compared to other hereditary syndromes 1, 4
Do not perform surveillance at low-volume centers, as all pancreatic surveillance should occur at high-volume centers with multidisciplinary teams experienced in managing high-risk individuals 5
Do not ignore new-onset diabetes, as this should prompt immediate investigation regardless of the patient's age or time since last surveillance 2, 3, 6